Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,179 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06560827RecruitingPhase 1
CAR-T Cells for Liver Cancer After Surgery
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
BeijingAges 18–75 - NCT06523179Recruiting
Liver cancer risk study for people with fatty liver disease
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
Milan, MilanoAges 45–75 - NCT06461793RecruitingPhase 2
Higher dose radiation with hormone therapy for high-risk prostate cancer
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT06309485RecruitingPhase 2
Study of WGI-0301 for advanced liver cancer
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06289270Recruiting
Bladder cancer and urine bacteria study
This study looks at bacteria in urine and the bladder to understand if they play a role in causing bladder cancer. Researchers will compare samples from men with bladder cancer and healthy controls.
Cairo, Giza GovernorateAges 18 years+ - NCT06276686RecruitingEarly Phase 1
Exercise With Chemoradiotherapy for Locally Advanced Rectal Cancer
This study tests whether adding regular exercise during your standard chemoradiotherapy can help the treatment work better for people with locally advanced rectal cancer. It is designed for patients who have already been offered this type of therapy before surgery.
Cottingham, East YorkshireAges 18 years+ - NCT06646198RecruitingPhase 2
TIPS with half-dose Donafenib for liver cancer with portal hypertension
This trial tests a treatment that combines a procedure called TIPS with a targeted therapy drug (Donafenib) at half strength. It is for people with advanced liver cancer that has spread into the portal vein and caused high blood pressure in the liver (portal hypertension). The goal is to see if this combination can help control the cancer and reduce complications.
Guangzhou, GuangdongAges 18–75 - NCT06215651RecruitingPhase 2
Testing cadonilimab and lenvatinib before liver cancer surgery
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06311929RecruitingPhase 4
Personalized treatment after liver cancer surgery
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
Wuhan, HubeiAges 18–75 - NCT05998135RecruitingPhase 2
Testing Atovaquone for Platinum-Resistant Ovarian Cancer
This trial tests whether a drug called atovaquone, already used for other conditions, can help people with ovarian cancer that no longer responds to platinum chemotherapy. It aims to find a new treatment option for this hard-to-treat type of cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06028022RecruitingPhase 2
Reishi mushroom for fatigue and joint/muscle pain in breast cancer
This trial tests whether a reishi mushroom extract can help reduce fatigue and joint or muscle pain in people with breast cancer who are taking aromatase inhibitors. If you have these symptoms, you may be able to join.
Albert Lea, MinnesotaAges 18 years+ - NCT05937295RecruitingPhase 1
Peptide vaccine plus immunotherapy for a specific cancer gene fusion
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Tübingen, Baden-WürtembergAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06120803RecruitingPhase 2
Esomeprazole for preventing radiation-induced esophagitis
This study tests whether a common heartburn medicine (esomeprazole) can help prevent or reduce painful swallowing caused by radiation for lung cancer. If you have stage 3 non-small cell lung cancer and are getting chemo and chest radiation, you may be able to join.
Chicago, IllinoisAges 18 years+ - NCT06051214Recruiting
Predicting blood clots in cancer patients at risk
This trial studies how your blood's ability to clot changes over time in people with certain cancers who have not yet started treatment. The goal is to better predict who might develop a dangerous blood clot, so that preventative steps can be taken.
Saint-HerblainAges 18 years+ - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT06121505RecruitingPhase 2
Low-dose radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05778253Recruiting
Blood and AI pathology to guide treatment in resectable lung cancer
This study checks whether special blood testing plus computer-based review of tumor slides can help plan care for lung squamous cell cancer that can be removed by surgery. It looks at patients who have not had prior cancer treatment and who meet specific stage and health criteria.
Changsha, HunanAges 18–75 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT05731622Recruiting
Mitomycin C in the bladder after ureteroscopy for UTUC
This trial studies whether a medicine called mitomycin C given as a one-time bladder treatment right after ureteroscopy can reduce later recurrence (measured by urine test results and “IVR rate”). It may help people with non-spreading UTUC who are having endoscopic procedures and are planned for this standard add-on treatment.
AmsterdamAges 18 years+ - NCT05710679Recruiting
Blood test predicts leftover cancer after intensified head and neck radiation
This study uses a blood test to see whether cancer DNA is still detectable after a stronger combination of radiation and chemotherapy for locally advanced head and neck cancer. The goal is to predict who may have “residual” (remaining) disease and help guide future care.
Clermont-Ferrand, Puy-de-DômeAges 18–80 - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05665738Recruiting
Two-visit HDR radiation to treat early prostate cancer
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
San Francisco, CaliforniaAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,179 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.